Immunogenicity and Safety of Quadrivalent Influenza Vaccine In 6 to 35 Months Population: a Randomized, Double-blind, Parallel-group Ⅱ Phase of Clinical Trials
Latest Information Update: 28 Dec 2023
At a glance
- Drugs Influenza virus vaccine quadrivalent Shanghai Institute of Biological Products (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Shanghai Institute of Biological Products
Most Recent Events
- 21 Dec 2023 Status changed from not yet recruiting to completed.
- 04 May 2020 New trial record